Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007


Posted on: 26 Oct 16

Leuven, Belgium, Oct. 26, 2016 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG) announced today that it received two transparency notifications pursuant to Article 14, first paragraph of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

Summary of the notifications

On October 21, 2016, TiGenix NV received two transparency notifications from RA Capital Management, LLC. In the first transparency notification RA Capital Management, LLC notifies the acquisition of 7,500,000 voting rights linked to securities in TiGenix NV (3.71% of the total voting rights) on March 14, 2016. As a result, the 3% threshold was crossed upwards. In the second transparency notification, RA Capital Management, LLC notifies the subsequent disposal of voting rights linked to securities on September 29, 2016, after which it held 6,039,076 voting rights in TiGenix NV (2.99% of the total voting rights) as of September 29, 2016 and consequently crossed downwards the 3% threshold.

Content of the first notification

Date of the notification: October 14, 2016.

Reason of the notification: acquisition of voting securities or voting rights.

Person subject to the notification requirement: RA Capital Management, LLC (a person that notifies alone).

Date on which the threshold was crossed: March 14, 2016.

Threshold that was crossed: 3%.

Denominator: 202,304,587.

Details of the notification:

Following the acquisition of voting rights linked to securities, the number of voting rights is as follows:

  • RA Capital Management, LLC holds 7,500,000 voting securities in TiGenix NV (3.71% of the total voting rights).

Chain of controlled undertakings through which the holdings are effectively held: RA Capital Management, LLC is not a controlled entity.

Additional information: RA Capital Management, LLC is the discretionary investment manager who exercises the voting rights.

Content of the second notification

Date of the notification: October 14, 2016.

Reason of the notification: disposal of voting securities or voting rights; downward crossing of the lowest threshold.

Person subject to the notification requirement: RA Capital Management, LLC (a person who notifies alone.

Date on which the threshold was crossed: September 29, 2016.

Threshold that was crossed: 3%.

Denominator: 202,304,587.

Details of the notification:

Following the disposal of voting securities, the number of voting rights is as follows:

  • RA Capital Management, LLC holds 6,039,076 voting securities in TiGenix NV (2.99% of the total voting rights).

Chain of controlled undertakings through which the holdings are effectively held: RA Capital Management, LLC is not a controlled entity.

Additional information: RA Capital Management, LLC is the discretionary investment manager who exercises the voting rights.

This press release and the above-mentioned transparency notifications can be consulted on our website:


For more information:

Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Our lead product candidate from the adipose-derived stem cell technology platform is Cx601, which is in registration with the European Medicines Agency for the treatment of complex perianal fistulas in Crohn's disease patients. Our adipose-derived stem cell product candidate Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. On July 4, 2016, TiGenix entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit http://www.tigenix.com .

GlobeNewswire
globenewswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.